
Canadian life sciences company Nirvana Life Sciences Inc. (CSE:NIRV), focused on research & development of non-addictive pain management and relapse prevention products for pain and addictions, has been granted approval to build its R&D facility in Vancouver by Canada’s governmental department of Health.
The Office For Controlled Substances & Authorizations Division reviewed the company’s proposed floor plan and design and concluded that the GMP level 9 secure facility satisfies all requirements.